Effect of Helicobacter pylori eradication therapy on the response of MALT-Gastric lymphoma


Habiba Dabbebi
Hanene Elloumi
Chaima Kechiche
Eya Hammemi
Imed Cheikh
Ali Jmaa


Introduction: The link between gastric mucosa-associated lymphoid tissue lymphoma (LG-MALT) and chronic Helicobacter Pylori (HP) infection had led to a real revolution in the management of the disease.

Aims: To study the results of the HP eradication therapy and to clarify its place in the tumor response.

Methods: A descriptive retrospective bicentric study, between January 2007 and December 2016, including patients with LG-MALT treated in the gastroenterology departments of Sahloul hospital in Sousse and Habib Bougtafa hospital in Bizerte, and having received treatment for eradication of HP.

Results: Sixty-three patients were included. The male/female sex ratio was 1.42. The average age was 58 years. The symptomatology was dominated by epigastric pain (96.8%). On digestive endoscopy, the most frequent location and appearance were gastric antrum (39.6%) and ulcerations (89%). The lymphoma was classified as stage IE and IIE1 in 81% and 19% of cases, respectively. The HP status was positive in all patients. The HP eradication rate was 82.5% after three anti-HP treatment courses. Complete remission of lymphoma was obtained in 81% of patients at 18 months. Non-response to HP eradication therapy was observed in 19% of patients. Non-responder patients had a longer diagnostic delay (p=0.02), more diffuse endoscopic involvement (p=0.001) and a more frequent appearance of large gastric folds (p=0.001).

Conclusion: The course of LG-MALT is determined by the treatment for the eradication of HP. Its success promotes remission of lymphoma.



  1. Ruskone-Fourmestraux A. Lymphome gastrique. Rev Prat 1997;47:848-54.
  2. Severson RK, Davis S. increasing incidence of primary gastric lymphoma. Cancer 1990;66(6):1283- 7. doi: 10.1002/1097-0142(19900915)66:6<1283::aidcncr2820660631>3.0.co;2-4.
  3. Ducreux M, Boutron MC, Piard F, Carli PM, Faivre J. A 15-years series of gastrointestinal non-Hodgkin’s lymphomas: a population-based study. Br J Cancer 1998;77(3):511-4. doi: 10.1038/bjc.1998.82.
  4. Gurney KA, Cartwright RA, Gilman EA. Descriptive epidemiology of gastrointestinal non-Hodgkin’s lymphoma in a population-based registry. Br J Cancer 1999;79(11- 12):1929-34. doi: 10.1038/sj.bjc.6690307.
  5. Caletti G, Fusaroli P, Togliani T. EUS in MALT lymphoma. Gastrointest Endosc. 2002;56(4, Supplement):S21-6. doi: 10.1016/s0016-5107(02)70081-3.
  6. Fusaroli P, Buscarini E, Peyre S, et al. Interobserver agreement in staging gastric malt lymphoma by EUS. Gastrointest Endosc. 2002;55(6):662-8. doi: 10.1067/ mge.2002.123421.
  7. Lehours P, Mégraud F. Infections à Helicobacter pylori et lymphome gastrique du MALT. Antibiotiques. 2005;7(2):97- 105. https://doi.org/10.1016/S1294-5501(05)80174-8.
  8. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment. Gut. 2001;48(3):297- 303. doi: 10.1136/gut.48.3.297.
  9. Georges Delsol. Classification OMS 2008 des lymphomes. Annales de pathologie (2008) 28S, S20—S24. Doi : 10.1016/j.annpat.2008.09.002.
  10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31(11):1860-1.
  11. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection--the Maastricht IV. Gut. 2012;61 (5):646-64. doi: 10.1136/gutjnl-2012-302084.
  12. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/ gutjnl-2016-312288. Epub 2016 Oct 5.
  13. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for posttreatment evaluation of gastric MALT lymphoma. Gut. 2003 Nov;52(11):1656. doi: 10.1136/gut.52.11.1656.
  14. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi 144-8. doi: 10.1093/annonc/mdt343.
  15. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61(5):646–64. doi: 10.1136/ gutjnl-2012-302084.
  16. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212– 238. doi: 10.1038/ ajg.2016.563.
  17. Ben Mansour K, Burucoa C, Zribi M, et al. Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. Ann Clin Microbiol Antimicrob. 2010;9:22. doi: 10.1186/1476-0711-9-22.
  18. Loghmari H, Bdioui F, Bouhlel W, et al. Comparaison de 2 protocoles de trithérapie anti-hélicobacter pylori incluant clarithromycine versus métronidazole. Étude prospective randomisée de 85 cas. La tunisie Medicale. 2012 ; 90(1):31–35.
  19. Moalla M, Chtourou L, Smaoui H, et al. Primary resistance of helicobacter pylori to clarithromycin in Tunisia. 29th United European Gastroenterology Week 2021 Poster Presentations. UEG journal 2021 october;9(S8):334. Available from: onlinelibrary.wiley.com/journal/20506414.
  20. Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa– Associated Lymphoid Tissue Lymphoma. Clin GastroenterolHepatol. 2010;8(2):105-10. doi: 10.1016/j.cgh.2009.07.017.
  21. Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter pylori and gastric MALT lymphoma. Gut 2002; 50(Suppl. 3):III19–24. doi: 10.1136/gut.50.suppl_3.iii19.
  22. Matysiak-Budnik T, Fabiani B, Hennequin C, et al. Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). Dig Liver Dis. 2018;50(2):124-31. doi: 10.1016/j.dld.2017.12.006.
  23. Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol WJG. 2007;13(26):3554- 66. doi: 10.3748/wjg.v13.i26.3554.
  24. Wundisch T, Thiede C, Morgner A, et al. Long-Term FollowUp of Gastric MALT Lymphoma After Helicobacter Pylori Eradication. J Clin Oncol. 2005; 23(31):8018-24. doi: 10.1200/JCO.2005.02.3903.
  25. Mendes LST, Attygalle AD, Wotherspoon AC. Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation. Gut. 2014;63(9):1526-7. doi: 10.1136/gutjnl-2014-307389.
  26. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: A clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97(10):2462‑73. doi: 10.1002/cncr.11415.
  27. Varas MJ, Fabra R, Abad R, et al. Endoscopic staging of lowgrade gastric MALT lymphoma. Rev Esp EnfermDig .2006; 98(3):189-95. doi: 10.4321/s1130-01082006000300005.
  28. Kim JS, Chung SJ, Choi YS, et al. Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer. 2007; 96(9):1324‑8. doi: 10.1038/sj.bjc.6603708.
  29. Sorrentino D, Ferraccioli GF, Labombarda A, et al. Helicobacter pylori, gastric MALT and B-cell clonality. Clin Exp Rheumatol. 1996;14 Suppl 14:S51-4.
  30. Fischbach W, Goebeler-Kolve M-E, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53(1):34-7. doi: 10.1136/gut.53.1.34.
  31. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507-13. doi: 10.1136/ gutjnl-2011-300495.
  32. Toyoda K, Maeshima AM, Nomoto J, et al. Mucosaassociated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results. Ann Hematol. 2019;98(7):1675-1687. doi: 10.1007/s00277-019-03671-5.
  33. Raderer M, Streubel B, Wöhrer S, Häfner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2006;55(5):616-8. doi: 10.1136/gut.2005.083022. Epub 2005 Nov 18.
  34. 3Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP, Boot H, Du MQ, Megraud F, et al. EGILS consensus report. Gastricextranodal marginal zone B-celllymphoma of MALT. Gut. 2011;60(6):747-58. doi: 10.1136/gut.2010.224949. Epub 2011 Feb 11.
  35. Levy M, Copie-Bergman C, Traulle C, et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa- associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol. 2002;97(2):292- 7. doi: 10.1111/j.1572-0241.2002.05460.x.
  36. Ryu KD, Kim GH, Park SO, et al. Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A SingleCenter Experience. Gut Liver. 2014;8(4):408-14. doi: 10.5009/gnl.2014.8.4.408. Epub 2013 Dec 24.